1 |
Fan X, Wang K, Lu Q, Lu Y, Sun J. Cell-Based Drug Delivery Systems Participate in the Cancer Immunity Cycle for Improved Cancer Immunotherapy. Small 2023;19:e2205166. [PMID: 36437050 DOI: 10.1002/smll.202205166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Kong L, Yang C, Zhang Z. Organism-Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy. Adv Sci (Weinh) 2023;10:e2204178. [PMID: 36424135 DOI: 10.1002/advs.202204178] [Reference Citation Analysis]
|
3 |
Lu R, Zheng Y, Wang M, Lin J, Zhao Z, Chen L, Zhang J, Liu X, Yin L, Chen Y. Reactive oxygen species-responsive branched poly (β-amino ester) with robust efficiency for cytosolic protein delivery. Acta Biomater 2022:S1742-7061(22)00553-0. [PMID: 36084925 DOI: 10.1016/j.actbio.2022.08.070] [Reference Citation Analysis]
|
4 |
Chen X, Gao M, An S, Zhao L, Han W, Wan W, Chen J, Ma S, Cai W, Cao Y, Ding D, Yang YY, Cheng L, Zheng Y. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. Nanomedicine: Nanotechnology, Biology and Medicine 2022;45:102591. [DOI: 10.1016/j.nano.2022.102591] [Reference Citation Analysis]
|
5 |
Lan M, Hou M, Yan J, Deng Q, Zhao Z, Lv S, Dang J, Yin M, Ji Y, Yin L. Cardiomyocyte-targeted anti-inflammatory nanotherapeutics against myocardial ischemia reperfusion (IR) injury. Nano Res 2022;:1-10. [PMID: 35915748 DOI: 10.1007/s12274-022-4553-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
6 |
Li X, Xu X, Huang K, Wu Y, Lin Z, Yin L. Hypoxia-Reinforced Antitumor RNA Interference Mediated by Micelleplexes with Programmed Disintegration. Acta Biomater 2022:S1742-7061(22)00326-9. [PMID: 35662669 DOI: 10.1016/j.actbio.2022.05.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|